ClinicalTrials.gg
CompletedNCT02412735MSB-DR003Updated Oct 19, 2022Results posted

Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain

A Phase 3 interventional study of Rexlemestrocel-L and Rexlemestrocel-L + HA Mixture in Degenerative Disc Disease, sponsored by Mesoblast, Ltd.. Completed at 48 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-19.

Sponsored by Mesoblast, Ltd. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
404
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 232 studies in Intervertebral Disc Degeneration with a site in United States — 41 open to participants now, 58 under way, 5 of them phase 3. Intervertebral Disc Degeneration · United States.

Enrollment
6th of 141
404 · median 57
Started
2015
with 8 others
Phase 3
16 of 232
3 open now
Registered
96th of 232
by date
Lead sponsor
6 of 232
Mesoblast, Ltd.

Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, this one is the 6th largest by enrollment of the 141 interventional ones that give a count, is one of 9 that started in 2015, is one of 16 in phase 3, and was the 96th registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

41 of the 232 studies in Intervertebral Disc Degeneration with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Intervertebral Disc Degeneration with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase 3 study designed to evaluate the safety and efficacy of Mesoblast's rexlemestrocel-L alone or combined with hyaluronic acid (HA) in participants with chronic low back pain (> 6 months) associated with moderate radiographic degenerative changes of a disc.

03

Conditions studied

  • Degenerative Disc Disease

Keywords

  • Chronic Lumbar Back Pain
  • Low back pain
  • Back pain
  • Degenerative Disc Disease
  • Injection of Degenerated Lumbar Disc
  • Intervertebral Disc Degeneration
  • Bone Diseases
  • Musculoskeletal Diseases
  • Nervous System Diseases
  • Neurologic Manifestations
  • Pain
  • Spinal Diseases
  • Stem Cells
  • Adult Stem Cells
  • Allogeneic Mesenchymal Precursor cells (MPCs)
  • Mesoblast
  • Hyaluronic Acid
  • Pharmaceutical Solutions
  • Adjuvants, Immunologic
  • Immunologic Factors
  • Pharmacologic Actions
  • Protective Agents
  • rexlemestrocel-L
  • Viscosupplements
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants 18 years of age and older
  • If female of , participant is non-pregnant, non-nursing, and agrees to use highly effective methods of for a minimum of 24 months post-treatment
  • Signed and country-appropriate privacy forms indicating participant is willing to undergo treatment and willing to be available for each examination scheduled over the study duration
  • Have documented diagnosis of moderate radiographic degeneration of an intervertebral disc from L1 to S1, with a disc suspected of causing chronic low back pain (CLBP) associated with moderate radiographic degeneration at a lumbar disc is defined as the following (participant must meet all of the listed conditions):

    1. Chronic low back pain for at least 6 months
    2. Have failed 6 months of conservative back pain care. (Conservative treatment regimens may include any or all of the following: initial rest, medications [e.g., anti-inflammatory, analgesics, narcotics/opioids, muscle relaxants], massage, acupuncture, chiropractic manipulations, activity modification, home-directed lumbar exercise program, and non-invasive pain control treatments or procedures)
    3. Have at a minimum undergone supervised physical therapy, such as daily walking routines, therapeutic exercises, and back education programs specifically for the treatment of low back pain and taken a pain medication for back pain (e.g. non-steroidal anti-inflammatory drug (NSAID) and/or opioid medication).
    4. Change from normal disc morphology of the index disc as defined by radiographic evaluation by the core imaging evaluation provider. Radiographs must show all of the following:
  • A modified Pfirrmann score of 3, 4, 5 or 6 on magnetic resonance imaging (MRI) at the index disc
  • Modic Grade II changes or less on MRI at the index disc
  • With or without contained disc protrusion at the index disc on MRI

    e. Low back pain of at least 40mm and not more than 90mm of 100mm on low back pain visual analogue scale (VAS) (average pain over 24 hours)

    f. Leg pain ≤20mm in both legs on a 100mm VAS scale

    g. Oswestry disability index (ODI) score of at least 30 and no more than 90 on a 100 point scale.

Exclusion criteria

Exclusion Criteria:

  • Female participants who are pregnant or nursing, or women planning to become pregnant in the first 24 months post-treatment
  • Extreme obesity, as defined by National Institutes of Health (NIH) Clinical Guidelines (BMI > 40)
  • Have undergone a surgical procedure (e.g. discectomy, intradiscal electrothermal therapy, intradiscal radiofrequency, artificial disc replacement, interbody fusion) on the disc at the index or adjacent level
  • Osteoporosis, as defined by dual-energy X-ray absorptiometry (DEXA) scan. A DEXA T-score of ≤ -2.5 will exclude the participant.
  • Any lumbar intradiscal injection, including , into the index or adjacent discs prior to treatment injection, with the exception of the following injections performed at least 2 weeks prior to study treatment:

    1. Contrast medium (discography or other diagnostic injection)
    2. NSAIDs
    3. Nerve-blocking anesthetics (e.g., lidocaine, bupivacaine)
    4. Antibiotics
    5. Saline
  • Have undergone a procedure affecting the structure/biomechanics of the index disc level (e.g., posterolateral fusion)
  • Active or tumor as source of symptoms or history of malignancy within the 5 years prior to enrolment on study
  • Have been a recipient of prior allogeneic stem cell/progenitor cell therapy for any indication or autologous stem cell/progenitor cell therapy or other biological intervention to repair the index intervertebral disc
  • An average baseline morphine equivalent dose (MED) of >75mg/day as determined by e-diary entries during the screening period
  • Taking systemic
  • A medical condition, serious intercurrent illness, or extenuating circumstance that would preclude participation in the study or potentially decrease survival or interfere with ambulation or rehabilitation.
  • Participants involved in spinal litigation, including workman's compensation, unless litigation is complete
  • Are transient or has a severe alcohol or substance abuse problem
  • nerve pain (e.g., chronic radiculopathy or neuropathy)
  • Clinically significant sacroiliac joint pain
  • Compressive pathology due to stenosis or disc protrusion on MRI with associated clinical symptoms defined as leg pain VAS>20mm out of 100mm or neurologic deficit on neurologic exam
  • Disc extrusion with a maximum dimension greater or equal to twice the posterior height of the disc, or disc sequestration in the lumbar spine on MRI as determined by radiographic core lab
  • Modified Pfirrmann score of 7 or 8 at any lumbar level (L1-S1) on MRI evaluation as determined by radiographic core lab
  • Symptomatic involvement of more than one lumbar disc
  • Symptomatic central vertebral canal stenosis as defined by neurogenic claudication
  • Spondylolisthesis or retrolisthesis Grade 2 and above or Spondylolysis at the index or adjacent level(s)
  • Lumbar spondylitis or other undifferentiated spondyloarthropathy affecting the index disc
  • Spinal deformity defined as lumbar scoliosis with a Cobb angle of the lumbar spine greater than 15 degrees
  • Any fracture of the spine at the index or adjacent levels that has not healed, or clinically compromised vertebral bodies at the index level due to current or past trauma
  • Facet pain at the index level or adjacent segments as determined by a diagnostic medial branch block (a facet block injection is not acceptable for making this determination) to rule out facet joint involvement.
  • Full thickness annular tears in the index level as determined by free flowing contrast media through the annulus fibrosis.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
404 participants (actual)

Study arms

  • Experimental
    Rexlemestrocel-L

    Participants received rexlemestrocel-L 2.0 mL injection of approximately 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with saline on Day 0 (Visit 2).

    Drug: Rexlemestrocel-L

  • Experimental
    Rexlemestrocel-L + HA

    Participants received rexlemestrocel-L 2.0 mL injection of approximately 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with hyaluronic acid (HA) solution on Day 0 (Visit 2).

    Drug: Rexlemestrocel-L + HA Mixture

  • Placebo comparator
    Placebo

    Participants received saline solution as matching-placebo on Day 0 (Visit 2).

    Drug: Placebo

Interventions

  • Rexlemestrocel-L injection

  • DrugRexlemestrocel-L + HA Mixture

    Rexlemestrocel-L was combined in 1:1 by-volume ratio with HA solution and the resulting mixture was injected

  • DrugPlacebo

    Saline control solution

06

What researchers measure

Primary outcomes

  1. Overall Treatment Success: Bayesian Estimated Response Rate

    Overall treatment success was determined based on number of responders who had composite response at both months 12 and 24 evaluated per specified criteria. A treatment responder with treatment success was defined as a participant who met the 3 criteria of a composite responder analysis as: 50% or greater reduction in the lower-back pain visual analogue scale (VAS) score; 15-point or greater reduction in the Oswestry Disability Index (ODI) score; and lack of post-treatment interventions at the treated level as of the study visit (Visits 6 \[12 months post-treatment\] and 8 \[24 months post-treatment\]). The average response rate (proportion of participants with response presented as Bayesian estimate\[BE\]) was based upon the average of multiple Bayesian simulations.

    Time frame: Up to 24 months

Secondary outcomes

  1. Effectiveness Based on Pain Responders: Bayesian Estimated Response Rate

    A participant was defined as a pain responder for a given study visit if they achieved at least a 50% reduction from Baseline in the lower-back pain VAS score (average pain over 24 hours), as reported during in-clinic assessment. The participant should be qualified as a pain responder at both 12 and 24 months post-treatment, and must not have received a post-treatment intervention through 24 months' follow-up. Any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.

    Time frame: Up to 24 months

  2. Effectiveness Based on Functional Responders: Bayesian Estimated Response Rate

    A participant was defined as a functional responder for a given study visit if they achieved at least a 15-point reduction from Baseline in ODI score, as reported during in-clinic assessment. The participant should be qualified as a functional responder at both 12 and 24 months post-treatment, and must not have received a post-treatment intervention through 24 months' follow-up; any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.

    Time frame: Up to 24 months

  3. Effectiveness Based on Treatment Success at 24 Months: Bayesian Estimated Response Rate

    A treatment responder with treatment success was defined as a participant who met the 3 conditions of a composite responder analysis as: 50% or greater reduction in the lower-back pain VAS score; 15-point or greater reduction in ODI score; and lack of post-treatment interventions at the treated level as of the study visit. The participants qualified as responders if they satisfied the above conditions at the 24-month follow-up visit alone. Any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.

    Time frame: Month 24

  4. Effectiveness Based on Minimal Pain Responders at 24 Months: Bayesian Estimated Response Rate

    A minimal pain responder was defined as a participant who achieved a lower-back pain VAS score (average pain over 24 hours) of 20 mm or less at the given study visit. The participants qualified as responders if they satisfied the above condition at 24 months post-treatment, and did not receive a post-treatment intervention through 24 months' follow-up. Any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.

    Time frame: Month 24

  5. Effectiveness Based on Time to First Intervention Over 24 Months

    The effectiveness of the study drug was evaluated based on its ability in increasing the time to additional interventions at the treated level over 24 months post-treatment. Kaplan-Meier estimates for the probability (expressed as a percentage) of participants to receive an intervention are presented.

    Time frame: Up to Month 24

  6. Effectiveness Based on Minimal Disability Responders at 24 Months: Bayesian Estimated Response Rate

    A minimal disability responder was defined as a participant who achieved an ODI score of 20% or less at the given study visit. The participants qualified as responders if they satisfied the above condition at 24 months post-treatment, and did not receive a post-treatment intervention through 24 months' follow-up. Any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.

    Time frame: Month 24

Other outcomes

  1. Mean Change From Baseline in Low Back Pain Visual Analog Scale (VAS) Score at 1, 3, 6, 12, 18, 24, and 36 Months

    Pain intensity was recorded on a horizontal 100 mm VAS and measured as the distance in millimeters from the left origin of the horizontal VAS line and the point indicated by the participant as representing their level of pain. A horizontal 100 mm VAS anchored on the left with the words "No Pain" and on the right with the words "Worst Possible Pain", was used to measure low back pain intensity. Scores were obtained by measuring the distance in millimeters from the left origin of the line (0) to the point indicated with a slash placed by the participant to indicate the participant's level of pain. VAS ranges from 0 to 100, with higher scores indicating worst possible pain. A negative change from baseline indicates improvement.

    Time frame: Months 1, 3, 6, 12, 18, 24, and 36

07

Results

Posted Jan 18, 2022

Participant flow

Starting on March 6, 2015, a total of 404 participants were enrolled at investigative sites in Australia and the United States.

Participant flow — Overall Study
MilestoneRexlemestrocel-LRexlemestrocel-L + HAPlacebo
Started143129132
Received treatment140128130
Completed978586
Not completed464446
Withdrew: Adverse event012
Withdrew: Withdrawal by subject232722
Withdrew: Investigator decision332
Withdrew: Lost to follow-up171118
Withdrew: Reason not specified322

Outcome measures

PrimaryOverall Treatment Success: Bayesian Estimated Response Rate

Overall treatment success was determined based on number of responders who had composite response at both months 12 and 24 evaluated per specified criteria. A treatment responder with treatment success was defined as a participant who met the 3 criteria of a composite responder analysis as: 50% or greater reduction in the lower-back pain visual analogue scale (VAS) score; 15-point or greater reduction in the Oswestry Disability Index (ODI) score; and lack of post-treatment interventions at the treated level as of the study visit (Visits 6 \[12 months post-treatment\] and 8 \[24 months post-treatment\]). The average response rate (proportion of participants with response presented as Bayesian estimate\[BE\]) was based upon the average of multiple Bayesian simulations.

Time frame:
Up to 24 months
Reported as:
Mean · BE proportion of participants
Overall Treatment Success: Bayesian Estimated Response Rate
BE proportion of participantsRexlemestrocel-LRexlemestrocel-L + HAPlacebo
Overall Treatment Success: Bayesian Estimated Response Rate0.267 ± 0.0380.335 ± 0.0430.313 ± 0.041
Statistical analysis
  • Rexlemestrocel-L vs Placebo ·
  • Rexlemestrocel-L + HA vs Placebo ·
SecondaryEffectiveness Based on Pain Responders: Bayesian Estimated Response Rate

A participant was defined as a pain responder for a given study visit if they achieved at least a 50% reduction from Baseline in the lower-back pain VAS score (average pain over 24 hours), as reported during in-clinic assessment. The participant should be qualified as a pain responder at both 12 and 24 months post-treatment, and must not have received a post-treatment intervention through 24 months' follow-up. Any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.

Time frame:
Up to 24 months
Reported as:
Mean · BE proportion of participants
Effectiveness Based on Pain Responders: Bayesian Estimated Response Rate
BE proportion of participantsRexlemestrocel-LRexlemestrocel-L + HAPlacebo
Effectiveness Based on Pain Responders: Bayesian Estimated Response Rate0.352 ± 0.0410.472 ± 0.0450.388 ± 0.044
Statistical analysis
  • Rexlemestrocel-L vs Placebo ·
  • Rexlemestrocel-L + HA vs Placebo ·
SecondaryEffectiveness Based on Functional Responders: Bayesian Estimated Response Rate

A participant was defined as a functional responder for a given study visit if they achieved at least a 15-point reduction from Baseline in ODI score, as reported during in-clinic assessment. The participant should be qualified as a functional responder at both 12 and 24 months post-treatment, and must not have received a post-treatment intervention through 24 months' follow-up; any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.

Time frame:
Up to 24 months
Reported as:
Mean · BE proportion of participants
Effectiveness Based on Functional Responders: Bayesian Estimated Response Rate
BE proportion of participantsRexlemestrocel-LRexlemestrocel-L + HAPlacebo
Effectiveness Based on Functional Responders: Bayesian Estimated Response Rate0.378 ± 0.0420.409 ± 0.0450.413 ± 0.044
Statistical analysis
  • Rexlemestrocel-L vs Placebo ·
  • Rexlemestrocel-L + HA vs Placebo ·
SecondaryEffectiveness Based on Treatment Success at 24 Months: Bayesian Estimated Response Rate

A treatment responder with treatment success was defined as a participant who met the 3 conditions of a composite responder analysis as: 50% or greater reduction in the lower-back pain VAS score; 15-point or greater reduction in ODI score; and lack of post-treatment interventions at the treated level as of the study visit. The participants qualified as responders if they satisfied the above conditions at the 24-month follow-up visit alone. Any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.

Time frame:
Month 24
Reported as:
Mean · BE proportion of participants
Effectiveness Based on Treatment Success at 24 Months: Bayesian Estimated Response Rate
BE proportion of participantsRexlemestrocel-LRexlemestrocel-L + HAPlacebo
Effectiveness Based on Treatment Success at 24 Months: Bayesian Estimated Response Rate0.353 ± 0.0420.425 ± 0.0450.391 ± 0.045
Statistical analysis
  • Rexlemestrocel-L vs Placebo ·
  • Rexlemestrocel-L + HA vs Placebo ·
SecondaryEffectiveness Based on Minimal Pain Responders at 24 Months: Bayesian Estimated Response Rate

A minimal pain responder was defined as a participant who achieved a lower-back pain VAS score (average pain over 24 hours) of 20 mm or less at the given study visit. The participants qualified as responders if they satisfied the above condition at 24 months post-treatment, and did not receive a post-treatment intervention through 24 months' follow-up. Any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.

Time frame:
Month 24
Reported as:
Mean · BE proportion of participants
Effectiveness Based on Minimal Pain Responders at 24 Months: Bayesian Estimated Response Rate
BE proportion of participantsRexlemestrocel-LRexlemestrocel-L + HAPlacebo
Effectiveness Based on Minimal Pain Responders at 24 Months: Bayesian Estimated Response Rate0.384 ± 0.0430.495 ± 0.0470.438 ± 0.046
Statistical analysis
  • Rexlemestrocel-L vs Placebo ·
  • Rexlemestrocel-L + HA vs Placebo ·
SecondaryEffectiveness Based on Time to First Intervention Over 24 Months

The effectiveness of the study drug was evaluated based on its ability in increasing the time to additional interventions at the treated level over 24 months post-treatment. Kaplan-Meier estimates for the probability (expressed as a percentage) of participants to receive an intervention are presented.

Time frame:
Up to Month 24
Reported as:
Number · percentage probability
Effectiveness Based on Time to First Intervention Over 24 Months
percentage probabilityRexlemestrocel-LRexlemestrocel-L + HAPlacebo
Effectiveness Based on Time to First Intervention Over 24 Months0.10990.10030.0913
Statistical analysis
  • Rexlemestrocel-L vs Placebo · Regression, Cox · p = 0.7842 · Hazard ratio (hr): 1.11 · 95% CI 0.50 to 2.46Hazard ratio and 95% confidence interval (CI) were calculated from a Cox regression model with treatment, pooled site, and opioid/non opioid use at Baseline as covariates.
  • Rexlemestrocel-L + HA vs Placebo · Regression, Cox · p = 0.8754 · Hazard ratio (hr): 0.93 · 95% CI 0.41 to 2.14Hazard ratio and 95% CI were calculated from a Cox regression model with treatment, pooled site, and opioid/non opioid use at Baseline as covariates.
SecondaryEffectiveness Based on Minimal Disability Responders at 24 Months: Bayesian Estimated Response Rate

A minimal disability responder was defined as a participant who achieved an ODI score of 20% or less at the given study visit. The participants qualified as responders if they satisfied the above condition at 24 months post-treatment, and did not receive a post-treatment intervention through 24 months' follow-up. Any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.

Time frame:
Month 24
Reported as:
Mean · BE proportion of participants
Effectiveness Based on Minimal Disability Responders at 24 Months: Bayesian Estimated Response Rate
BE proportion of participantsRexlemestrocel-LRexlemestrocel-L + HAPlacebo
Effectiveness Based on Minimal Disability Responders at 24 Months: Bayesian Estimated Response Rate0.394 ± 0.0430.367 ± 0.0450.440 ± 0.045
Statistical analysis
  • Rexlemestrocel-L vs Placebo ·
  • Rexlemestrocel-L + HA vs Placebo ·
Other pre-specifiedMean Change From Baseline in Low Back Pain Visual Analog Scale (VAS) Score at 1, 3, 6, 12, 18, 24, and 36 Months

Pain intensity was recorded on a horizontal 100 mm VAS and measured as the distance in millimeters from the left origin of the horizontal VAS line and the point indicated by the participant as representing their level of pain. A horizontal 100 mm VAS anchored on the left with the words "No Pain" and on the right with the words "Worst Possible Pain", was used to measure low back pain intensity. Scores were obtained by measuring the distance in millimeters from the left origin of the line (0) to the point indicated with a slash placed by the participant to indicate the participant's level of pain. VAS ranges from 0 to 100, with higher scores indicating worst possible pain. A negative change from baseline indicates improvement.

Time frame:
Months 1, 3, 6, 12, 18, 24, and 36
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in Low Back Pain Visual Analog Scale (VAS) Score at 1, 3, 6, 12, 18, 24, and 36 Months
score on a scaleRexlemestrocel-LRexlemestrocel-L + HAPlacebo
Change from Baseline at Month 1-13.6 ± 2.14-17.3 ± 2.30-13.9 ± 2.32
Change from Baseline at Month 3-19.1 ± 2.26-22.5 ± 2.41-17.6 ± 2.40
Change from Baseline at Month 6-22.4 ± 2.34-24.9 ± 2.51-18.6 ± 2.48
Change from Baseline at Month 12-23.3 ± 2.38-27.4 ± 2.55-19.0 ± 2.51
Change from Baseline at Month 18-23.7 ± 2.56-25.1 ± 2.74-19.2 ± 2.70
Change from Baseline at Month 24-20.8 ± 2.55-25.9 ± 2.74-18.3 ± 2.70
Change from Baseline at Month 36-22.9 ± 2.62-25.1 ± 2.81-19.0 ± 2.77
Statistical analysis
  • Rexlemestrocel-L vs Placebo · Mixed Model for Repeated Measures (MMRM) · p = 0.9072 · Least squares mean difference: 0.4 · 95% CI -5.71 to 6.43MMRM was used with fixed effects of pooled site,baseline use of opioids,treatment,visit,treatment-by-visit interaction\&continuous covariate baseline.
  • Rexlemestrocel-L + HA vs Placebo · MMRM · p = 0.2883 · Least squares mean difference: -3.3 · 95% CI -9.51 to 2.83MMRM was used with fixed effects of pooled site,baseline use of opioids,treatment,visit,treatment-by-visit interaction\&continuous covariate baseline.
  • Rexlemestrocel-L vs Placebo · MMRM · p = 0.6314 · Least squares mean difference: -1.6 · 95% CI -7.90 to 4.80MMRM was used with fixed effects of pooled site,baseline use of opioids,treatment,visit,treatment-by-visit interaction\&continuous covariate baseline.
  • Rexlemestrocel-L + HA vs Placebo · MMRM · p = 0.1366 · Least squares mean difference: -4.9 · 95% CI -11.37 to 1.56MMRM was used with fixed effects of pooled site,baseline use of opioids,treatment,visit,treatment-by-visit interaction\&continuous covariate baseline.
  • Rexlemestrocel-L vs Placebo · MMRM · p = 0.2497 · Least squares mean difference: -3.9 · 95% CI -10.43 to 2.72MMRM was used with fixed effects of pooled site,baseline use of opioids,treatment,visit,treatment-by-visit interaction\&continuous covariate baseline.
  • Rexlemestrocel-L + HA vs Placebo · MMRM · p = 0.0666 · Least squares mean difference: -6.3 · 95% CI -13.00 to 0.43MMRM was used with fixed effects of pooled site,baseline use of opioids,treatment,visit,treatment-by-visit interaction\&continuous covariate baseline.
  • Rexlemestrocel-L vs Placebo · MMRM · p = 0.2147 · Least squares mean difference: -4.2 · 95% CI -10.91 to 2.46MMRM was used with fixed effects of pooled site,baseline use of opioids,treatment,visit,treatment-by-visit interaction\&continuous covariate baseline.
  • Rexlemestrocel-L + HA vs Placebo · MMRM · p = 0.0162 · Least squares mean difference: -8.4 · 95% CI -15.19 to -1.55MMRM was used with fixed effects of pooled site,baseline use of opioids,treatment,visit,treatment-by-visit interaction\&continuous covariate baseline.
  • Rexlemestrocel-L vs Placebo · MMRM · p = 0.2230 · Least squares mean difference: -4.5 · 95% CI -11.69 to 2.74MMRM was used with fixed effects of pooled site,baseline use of opioids,treatment,visit,treatment-by-visit interaction\&continuous covariate baseline.
  • Rexlemestrocel-L + HA vs Placebo · MMRM · p = 0.1152 · Least squares mean difference: -5.9 · 95% CI -13.27 to 1.45MMRM was used with fixed effects of pooled site,baseline use of opioids,treatment,visit,treatment-by-visit interaction\&continuous covariate baseline.
  • Rexlemestrocel-L vs Placebo · MMRM · p = 0.4884 · Least squares mean difference: -2.5 · 95% CI -9.75 to 4.67MMRM was used with fixed effects of pooled site,baseline use of opioids,treatment,visit,treatment-by-visit interaction\&continuous covariate baseline.
  • Rexlemestrocel-L + HA vs Placebo · MMRM · p = 0.0426 · Least squares mean difference: -7.6 · 95% CI -14.98 to -0.25MMRM was used with fixed effects of pooled site,baseline use of opioids,treatment,visit,treatment-by-visit interaction\&continuous covariate baseline.
  • Rexlemestrocel-L vs Placebo · MMRM · p = 0.3056 · Least squares mean difference: -3.9 · 95% CI -11.27 to 3.54MMRM was used with fixed effects of pooled site,baseline use of opioids,treatment,visit,treatment-by-visit interaction\&continuous covariate baseline.
  • Rexlemestrocel-L + HA vs Placebo · MMRM · p = 0.1184 · Least squares mean difference: -6.0 · 95% CI -13.59 to 1.54MMRM was used with fixed effects of pooled site,baseline use of opioids,treatment,visit,treatment-by-visit interaction\&continuous covariate baseline.

Adverse events

Collected over Up to approximately 38 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rexlemestrocel-L0/143 (0%)17/140 (12.1%)111/140 (79.3%)
Rexlemestrocel-L + HA0/129 (0%)15/128 (11.7%)100/128 (78.1%)
Placebo0/132 (0%)10/130 (7.7%)98/130 (75.4%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventRexlemestrocel-LRexlemestrocel-L + HAPlacebo
Back painMusculoskeletal and connective tissue disorders0/1400/1284/130
Acute myocardial infarctionCardiac disorders0/1402/1280/130
Myocardial infarctionCardiac disorders0/1402/1280/130
AppendicitisInfections and infestations2/1401/1281/130
DiverticulitisInfections and infestations1/1401/1280/130
PneumoniaInfections and infestations0/1401/1280/130
ArthralgiaMusculoskeletal and connective tissue disorders0/1401/1280/130
Coronary artery diseaseCardiac disorders0/1401/1280/130
Patella fractureInjury, poisoning and procedural complications0/1401/1280/130
MigraineNervous system disorders0/1401/1280/130
Most frequent other events
Most frequent other events
EventRexlemestrocel-LRexlemestrocel-L + HAPlacebo
Back painMusculoskeletal and connective tissue disorders51/14056/12848/130
Pain in extremityMusculoskeletal and connective tissue disorders19/14017/12819/130
ArthralgiaMusculoskeletal and connective tissue disorders13/14015/12813/130
HypoesthesiaNervous system disorders10/1408/12812/130
ParesthesiaNervous system disorders11/1405/1284/130
Muscle spasmsMusculoskeletal and connective tissue disorders10/1407/12810/130
Neck painMusculoskeletal and connective tissue disorders5/1406/12810/130
NauseaGastrointestinal disorders5/1407/1284/130

Baseline characteristics

The Intent-to-treat (ITT) Analysis Set included all participants who were randomized, regardless of whether or not the participant was treated, or post-treatment measures were performed.

Age, Continuous
Age, Continuous(years)Rexlemestrocel-LRexlemestrocel-L + HAPlaceboTotal
Mean42.1 ± 10.8142.9 ± 11.6643.3 ± 10.4542.8 ± 10.96
Sex: Female, Male
Sex: Female, Male(Participants)Rexlemestrocel-LRexlemestrocel-L + HAPlaceboTotal
Female605461175
Male837571229
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rexlemestrocel-LRexlemestrocel-L + HAPlaceboTotal
Hispanic or Latino941124
Not Hispanic or Latino133121119373
Unknown or Not Reported1427
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rexlemestrocel-LRexlemestrocel-L + HAPlaceboTotal
American Indian or Alaska Native0011
Asian0437
Native Hawaiian or Other Pacific Islander0000
Black or African American66618
White133118118369
More than one race0000
Unknown or Not Reported4149
08

Study locations

48 sites
  • Alabama Clinical Therapeutics, LLC
    Birmingham, Alabama 35235, United States
  • Tennessee Valley Pain Consultants
    Huntsville, Alabama 35801, United States
  • Arizona Pain Specialists
    Scottsdale, Arizona 85258, United States
  • Physicians Research Group
    Tempe, Arizona 85284-2604, United States
  • TriWest Research Associates, LLC
    El Cajon, California 92020-4124, United States
  • Memorial Orthopaedics Surgical Group
    Long Beach, California 90806, United States
  • Newport Beach Headache and Pain
    Newport Beach, California 92660, United States
  • Institute for Regenerative Medicine and Clinical Research
    Pasadena, California 91105, United States
  • UC Davis Spine Center
    Sacramento, California 95816, United States
  • Orthopedic Pain Specialists
    Santa Monica, California 90403, United States
  • The Spine Institute
    Santa Monica, California 90403, United States
  • Summit Pain Alliance
    Santa Rosa, California 95401, United States
  • Integrated Pain Management
    Walnut Creek, California 94598, United States
  • Denver Back Pain Specialists, LLC
    Greenwood Village, Colorado 80111, United States
  • George Washington University Medical Center
    Washington, District of Columbia 20037, United States
  • Coastal Clinical Research Specialists
    Fernandina Beach, Florida 32034, United States
  • Shrock Orthopedic Research, LLC
    Fort Lauderdale, Florida 33316, United States
  • Holy Cross Orthopedics Institute
    Oakland Park, Florida 33334, United States
  • Emory Orthopaedics & Spine Center
    Atlanta, Georgia 30329, United States
  • Georgia Institute for Clinical Research, LLC
    Marietta, Georgia 30060, United States
  • Injury Care Medical Center
    Boise, Idaho 83713, United States
  • Millennium Pain Center
    Bloomington, Illinois 61701, United States
  • Otrimed Clinical Research
    Edgewood, Kentucky 41017, United States
  • Orthopedic Specialists of Louisiana
    Shreveport, Louisiana 71103, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • MAPS Applied Research Center
    Shakopee, Minnesota 55379, United States
  • Innovative Pain Care Center
    Las Vegas, Nevada 89129, United States
  • University Clinical Research
    Somerset, New Jersey 08873, United States
  • Ainsworth Institute of Pain Management
    New York, New York 10022, United States
  • Rochester Regional Health
    Rochester, New York 14626, United States
  • Carolina Neurosurgery and Spine Associates
    Charlotte, North Carolina 28204, United States
  • On Site Clinical Solutions, LLC
    Morrisville, North Carolina 28117, United States
  • The Center for Clinical Research/ Carolinas Pain Institute
    Winston-Salem, North Carolina 27103, United States
  • Cleveland Clinic
    Cleveland, Ohio 44106, United States
  • DOC Clinical Research
    Dayton, Ohio 45432, United States
  • Clinical Investigations, LLC
    Edmond, Oklahoma 73013, United States
  • Orthopaedic and Spine Specialists
    York, Pennsylvania 17402, United States
  • RI Hospital-Comprehensive Spine Center
    Providence, Rhode Island 02903, United States
  • Clinical Trials of South Carolina
    Charleston, South Carolina 29406, United States
  • Greenville Pharmaceutical Research, Inc.
    Charleston, South Carolina 29406, United States
  • Texas Back Institute
    Plano, Texas 75093, United States
  • Spine Team Texas
    Southlake, Texas 76092, United States
  • Precision Spine Care
    Tyler, Texas 75701, United States
  • Ericksen Research & Development, LLC
    Bountiful, Utah 84010, United States
  • the SMART Clinic
    Draper, Utah 84020, United States
  • Hope Research Institute
    Saint George, Utah 84790, United States
  • Virginia iSpine Physicians, PC
    Richmond, Virginia 23235, United States
  • Monash Medical Center
    Clayton, Victoria 3168, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in May 2020, 62 months.

Results were first posted in Jan 2022, 1 year 8 months after primary completion. A results delay was requested in May 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2015
First posted
Apr 9, 2015
StartActual
Mar 6, 2015
Primary completionActual
May 15, 2020
CompletionActual
Jun 15, 2021
Results delay requested
May 24, 2021
Results first posted
Jan 18, 2022
Last update
Oct 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02412735
Lead sponsor
Mesoblast, Ltd.
Collaborators
Quintiles, Inc.
Responsible party
Sponsor
First posted
Apr 9, 2015
Start date
Mar 6, 2015
Primary completion
May 15, 2020
Completion
Jun 15, 2021
Results posted
Jan 18, 2022
Last update
Oct 19, 2022

Study contacts

Roger Brown
study director · Mesoblast, Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rexlemestrocel-l

Start the discussion